This Amendment No. 3 (this Amendment) amends and supplements the Tender Offer
Statement on Schedule TO filed by Augusta Merger Sub, Inc., a Delaware corporation (Purchaser), a wholly owned subsidiary of Allergan Holdco US, Inc., a Delaware corporation (Parent), and an indirect wholly owned subsidiary
of Allergan plc, an Irish public limited company (Allergan), with the Securities and Exchange Commission on September 26, 2016 (together with any subsequent amendments and supplements thereto, the Schedule TO). The
Schedule TO relates to the tender offer by Purchaser for all of the outstanding shares of common stock, par value $0.0001 per share (Shares), of Vitae Pharmaceuticals, Inc., a Delaware corporation (Vitae), at a price of
$21.00 per share, net to the seller in cash, without interest and less any applicable withholding taxes, upon the terms and subject to the conditions set forth in the offer to purchase dated September 26, 2016 (the Offer to
Purchase), a copy of which is attached as Exhibit (a)(1)(A), and in the related letter of transmittal (the Letter of Transmittal), a copy of which is attached as Exhibit (a)(1)(B), which, as each may be amended or supplemented from
time to time, collectively constitute the Offer.
All the information set forth in the Offer to Purchase, including Schedule I
thereto, is incorporated by reference herein in response to Items 1 through 9 and Item 11 of this Schedule TO, and is supplemented by the information specifically provided in this Amendment.
Capitalized terms used but not defined in this Amendment shall have the meanings assigned to such terms in the Schedule TO.
Items 1 through 9; Item 11.
through 9 and 11 of the Schedule TO are hereby amended and supplemented as follows:
The Offer and withdrawal rights expired as
scheduled at the end of the day midnight, New York City time, on October 24, 2016 (one minute after 11:59 P.M., New York City time, on October 24, 2016). The Offer was not extended. The Depositary has advised that, as of the expiration of
the Offer, 26,235,210 Shares, representing approximately 90.3 percent of the Shares issued and outstanding as of the expiration of the Offer, had been validly tendered and not validly withdrawn pursuant to the Offer. In addition, Notices of
Guaranteed Delivery had been delivered for 836,595 Shares, representing approximately 2.9 percent of the Shares issued and outstanding as of the expiration of the Offer. The number of Shares tendered (excluding Shares delivered pursuant to Notices
of Guaranteed Delivery) satisfies the Minimum Tender Condition. As the Minimum Tender Condition and each of the other conditions of the Offer have been satisfied, Purchaser has accepted for payment all Shares that were validly tendered and not
validly withdrawn pursuant to the Offer.
Following expiration of the Offer and acceptance for payment of the Shares, Parent intends to
complete its acquisition of Vitae later today by consummating the Merger pursuant to the terms of the Merger Agreement and without a meeting of stockholders of Vitae in accordance with Section 251(h) of the DGCL. At the Effective Time,
(x) Purchaser will be merged with and into Vitae, with Vitae continuing as the Surviving Corporation and a wholly owned subsidiary of Parent, and (y) each Share issued and outstanding immediately prior to the Effective Time (other than
Shares held (i) in the treasury of Vitae or by Parent or Purchaser, which Shares will be cancelled and will cease to exist or (ii) by stockholders who validly exercise appraisal rights under Delaware law with respect to such Shares) will
be automatically cancelled and converted into the right to receive $21.00 per Share, net to the seller in cash, without interest and less any applicable withholding taxes. As a result of the Merger, Vitae will cease to be a publicly traded company
and the Shares will no longer be listed on The NASDAQ Stock Market.
On October 25, 2016, Allergan issued a press release announcing
the expiration and results of the Offer and the intention to consummate of the Merger. The press release is attached as Exhibit (a)(1)(L) hereto, and is incorporated herein by reference.
Item 12 of the
Schedule TO is hereby amended and supplemented by adding the following exhibit:
||Press Release issued by Allergan plc on October 25, 2016.|